Weight gain stopping/switch rules for antiretroviral clinical trials
François Venter, Simiso Sokhela, Alexandra Calmy, Luckyboy Mkhondwane, Bronwyn Bosch, Nomathemba Chandiwana, Andrew Hill, Kenly Sekwese, Nkuli Mashabane, Anton Pozniak, Saye Khoo, Mohammed K. Ali, Éric Delaporte, Samanta Lalla-Edwards, Polly Clayden, Vincent C. Marconi, Mark J. Siedner, Marta Boffito, Celicia Serenata, Mary Carman, Simon Collins
Abstract
Obesity develops in a substantial number of people initiating and maintaining modern antiretroviral therapy. The comorbidities associated with obesity make significant weight gain and metabolic changes a major consideration in clinical trials studying different regimens' potency and safety. It is as yet unclear what role individual antiretrovirals or classes play in weight gain but the issue is a complex one for clinical trial design, especially when deciding when "too much" weight has been gained, in a context where we do not yet know if switching to alternative regimens will slow, halt or reverse weight gain or metabolic changes. In addition, clinician and trial participant opinion on acceptable weight gain may differ. We offer preliminary guidance for discussion for future antiretroviral clinical trial design.